Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





First-Ever Highly Sensitive Antibody Tests Could Detect Infection with All Known Human Coronaviruses, Including New SARS-CoV-2 Variants

By LabMedica International staff writers
Posted on 19 Feb 2021
Scientists have set the stage for the development of highly sensitive antibody tests for infection with all known human coronaviruses, including new variants of SARS-CoV-2.

Scientists at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health (New York, NY, USA) have developed the HCoV-Peptide consisting of three million immune markers on a glass chip and covering proteins of all known human coronaviruses, including the SARS-CoV-2. More...
In collaboration with a team at the SunYat-Sen University (Guangzhou, China), the CII researchers have identified 29 immune signatures specific to SARS-CoV-2. These genetic fingerprints (peptides) provide the blueprint for tests that will be used for diagnostics and surveillance. Current antibody tests for SARS-CoV-2 infection may generate false-positive results because of cross-reactivity with seasonal coronaviruses responsible for the common cold, as well as MERS-CoV and SARS-CoV-1.

To develop the HCoV-Peptide array, the researchers first analyzed blood samples taken from individuals with asymptomatic, mild, or severe SARS-CoV-2 infections, and controls including healthy individuals and those exposed to SARS-CoV-1 and seasonal coronaviruses. An analysis of all approximately 170,000 peptides related to known human coronaviruses yielded 29 peptides with the strongest and most specific reactivity with SARS-CoV-2. Next, they validated their test using a second set of blood samples, including those from confirmed cases of SARS-CoV-2, those with antibodies to other human coronaviruses, and healthy individuals. The new test has a 98% specificity and sensitivity. Immune signatures were present from eight days after onset of COVID-19 symptoms to as long as six to seven months after infection.

“This work will allow us and others to build inexpensive, easy-to-use blood tests that can provide data for exposure as well as immunity,” said author Nischay Mishra, PhD, assistant professor of epidemiology at the Columbia Mailman School.

Related Links:
Columbia University Mailman School of Public Health
SunYat-Sen University



Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.